Supercharged immune cells take on Hard-to-Treat myeloma

NCT ID NCT06066359

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This trial tests a new approach for people with multiple myeloma that has come back or not responded to treatment. Doctors take immune cells from donated cord blood, genetically engineer them to better recognize and attack myeloma cells, and give them back to the patient along with chemotherapy. The study aims to find the safest dose and see if the cells can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cord blood-derived natural killer cells genetically engineered with NY-ESO-1 TCR/IL-15, given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to: If successful, this could provide a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 44 participants, so the treatment may not work for everyone and could cause serious side effects. The cells are experimental and long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA RELAPSED/REFRACTORY MYELOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.